These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25930110)

  • 1. Perspective on multi-target antiplatelet therapies: high content phenotypic screening as an unbiased source of novel polypharmacological strategies.
    Landré V; Amelio I; Barlev NA; Knight RA; Lisitsa A; Melino G; Antonov AV
    Mini Rev Med Chem; 2015; 15(8):622-9. PubMed ID: 25930110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.
    Tautz L; Senis YA; Oury C; Rahmouni S
    Bioorg Med Chem; 2015 Jun; 23(12):2786-97. PubMed ID: 25921264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet Signaling Pathways and New Inhibitors.
    Grover SP; Bergmeier W; Mackman N
    Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):e28-e35. PubMed ID: 29563117
    [No Abstract]   [Full Text] [Related]  

  • 4. Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases.
    Yeung J; Li W; Holinstat M
    Pharmacol Rev; 2018 Jul; 70(3):526-548. PubMed ID: 29925522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible Molecular Targets of Novel Ruthenium Complexes in Antiplatelet Therapy.
    Jayakumar T; Hsu CY; Khamrang T; Hsia CH; Hsia CW; Manubolu M; Sheu JR
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29925802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet Function in Cardiovascular Disease: Activation of Molecules and Activation by Molecules.
    Khodadi E
    Cardiovasc Toxicol; 2020 Feb; 20(1):1-10. PubMed ID: 31784932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD.
    Müller KA; Chatterjee M; Rath D; Geisler T
    Thromb Haemost; 2015 Aug; 114(3):498-518. PubMed ID: 26224127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet biology and functions: new concepts and clinical perspectives.
    van der Meijden PEJ; Heemskerk JWM
    Nat Rev Cardiol; 2019 Mar; 16(3):166-179. PubMed ID: 30429532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinal vein occlusion disease and platelet activation: will antiplatelet therapy be a promising therapeutic strategy for patients with retinal vein occlusion disease in the future?
    Fateh-Moghadam S; Gawaz M
    Thromb Haemost; 2007 Feb; 97(2):169-70. PubMed ID: 17264941
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacological inhibition of platelet reactivity. Clinical and pharmacodynamic effects.
    Vallés J; Moscardo A; Madrid I; Santos MT
    Curr Vasc Pharmacol; 2013 Jul; 11(4):431-47. PubMed ID: 23905638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future innovations in anti-platelet therapies.
    Barrett NE; Holbrook L; Jones S; Kaiser WJ; Moraes LA; Rana R; Sage T; Stanley RG; Tucker KL; Wright B; Gibbins JM
    Br J Pharmacol; 2008 Jul; 154(5):918-39. PubMed ID: 18587441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
    Jennings LK
    Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet therapy: targeting the TxA2 pathway.
    Fontana P; Zufferey A; Daali Y; Reny JL
    J Cardiovasc Transl Res; 2014 Feb; 7(1):29-38. PubMed ID: 24353037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic.
    Xiang Q; Pang X; Liu Z; Yang G; Tao W; Pei Q; Cui Y
    Pharmacol Ther; 2019 Nov; 203():107393. PubMed ID: 31356909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Antiplatelet Agents in Cardiovascular Disease.
    Tscharre M; Michelson AD; Gremmel T
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):191-200. PubMed ID: 31960728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet activation, and antiplatelet targets and agents: current and novel strategies.
    Xiang YZ; Xia Y; Gao XM; Shang HC; Kang LY; Zhang BL
    Drugs; 2008; 68(12):1647-64. PubMed ID: 18681489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of Key Antiplatelet Pathways by Bioactive Compounds with Minimal Bleeding Risk.
    Fuentes E; Wehinger S; Trostchansky A
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanisms of platelet activation and development of antiplatelet agents].
    Cazenave JP; Gachet C; Lanza F
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1501-6. PubMed ID: 9092410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of platelet activation-inhibitory drugs.
    Rao GH; Rao AT
    Indian J Physiol Pharmacol; 1994 Apr; 38(2):69-84. PubMed ID: 8063366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet physiology and antiplatelet agents.
    Thijs T; Nuyttens BP; Deckmyn H; Broos K
    Clin Chem Lab Med; 2010 Dec; 48 Suppl 1():S3-13. PubMed ID: 21054192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.